TOMS Shoes founder is pledging $100 million for psychedelic research – Here's why he's doing it.Market Watch • 06/21/23
Cybin to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual ConferenceBusiness Wire • 06/15/23
Cybin Announces Scientific Management Transition Following Achievement of Final Adelia MilestonesBusiness Wire • 06/05/23
Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital FundBusiness Wire • 05/30/23
Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic TherapyBusiness Wire • 04/12/23
Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development ProgramBusiness Wire • 02/28/23
Cybin shares rise as 3Q results meet expectations, analysts maintain ‘positive bias outlook'Proactive Investors • 02/15/23
Cybin Inc. Reports Third Quarter Financial Results and Recent Business HighlightsBusiness Wire • 02/14/23
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004Business Wire • 02/01/23
Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the BrainBusiness Wire • 01/18/23
Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004Business Wire • 01/12/23